Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VenEx: Venetoclax + Azacitidine in AML
NCT04267081Phase 2Completed
- Sponsor
- Helsinki University Hospital
- Start
- Feb 2020
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Helsinki University Hospital. Primary endpoint: Complete Remission/Complete Remission with Incomplete Hematologic Recovery Rate. Started Feb 2020; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04267081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267081.